Baykan Cenk, Mete Çiftseven Melike, Keskindemirci Gonca, Özbörü Aşkan Öykü, Kayı Alev Bakır, Karaman Serap, Ünüvar Ayşegül, Tuğcu Deniz, Gokcay Emine Gulbin, Arslan Merve, Karakaş Zeynep, Tanyıldız Hikmet Gülşah
Department of Child Health and Diseases, Istanbul Medical Faculty, İstanbul University, 34104 Istanbul, Turkey.
Division of Social Pediatrics, Department of Child Health and Diseases, Istanbul Medical Faculty, İstanbul University, 34098 Istanbul, Turkey.
Children (Basel). 2024 Dec 22;11(12):1557. doi: 10.3390/children11121557.
Propranolol is an effective treatment option for infantile hemangiomas, but there is still insufficient information about neurodevelopmental side effects of propranolol. In our study, the neurodevelopmental levels of infantile hemangioma patients receiving propranolol treatment were examined using the Bayley-III test.
In our single-center, cross-sectional study, patients were recruited between 1 January 2020 and 31 December 2023. In total, 40 children (n1) diagnosed with hemangioma who received propranolol treatment and 31 children (n2) who were only under observation were included. A control group of 31 healthy children (n3) matched for age and gender was also included. The demographic, clinical, perinatal, and postnatal characteristics of the total 102 children were recorded from their medical records. Neurodevelopmental levels were assessed with the Bayley-III test. The significance level was set at ( < 0.05).
The Bayley-III test composite and percentile scores were used to evaluate the neurodevelopmental levels. Significant differences in motor functions were found between the treated and untreated groups compared to the healthy control group ( = 0.006 and = 0.006). However, no significant differences were found in cognitive, language, and social-emotional skills. Cognitive, language, and motor functions were associated with maternal education level, and additionally, cognitive functions were also associated with paternal education level.
Propranolol has a relatively safer side effect profile, and therefore, it has been described as a safe agent. In our study, no significant effect of propranolol on neurodevelopment was observed. The difference in motor skills shown was mainly between the healthy control group (n3) and the treated and untreated group (n1 and n2), which led to the conclusion that the relevant difference could be due to factors other than propranolol itself.
普萘洛尔是治疗婴儿血管瘤的一种有效选择，但关于普萘洛尔的神经发育副作用仍有不足的信息。在我们的研究中，使用贝利婴幼儿发展量表第三版（Bayley-III）测试来检查接受普萘洛尔治疗的婴儿血管瘤患者的神经发育水平。
在我们的单中心横断面研究中，于2020年1月1日至2023年12月31日招募患者。总共纳入了40名接受普萘洛尔治疗的血管瘤确诊儿童（n1）和31名仅接受观察的儿童（n2）。还纳入了31名年龄和性别匹配的健康儿童作为对照组（n3）。从这102名儿童的病历中记录其人口统计学、临床、围产期和产后特征。使用贝利婴幼儿发展量表第三版（Bayley-III）测试评估神经发育水平。显著性水平设定为（<0.05）。
使用贝利婴幼儿发展量表第三版（Bayley-III）测试的综合得分和百分位数得分来评估神经发育水平。与健康对照组相比，治疗组和未治疗组在运动功能方面存在显著差异（=0.006和=0.006）。然而，在认知、语言和社会情感技能方面未发现显著差异。认知、语言和运动功能与母亲教育水平相关，此外，认知功能还与父亲教育水平相关。
普萘洛尔具有相对更安全的副作用特征，因此被描述为一种安全的药物。在我们的研究中，未观察到普萘洛尔对神经发育有显著影响。所显示的运动技能差异主要存在于健康对照组（n3）与治疗组和未治疗组（n1和n2）之间，由此得出结论，相关差异可能是由普萘洛尔本身以外的因素导致的。
